ArticleBreast cancer research : BCR2019

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.

Miguel Quintela-Fandino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.